SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride (0.9%) provides isotonic sodium and chloride ions, expanding extracellular fluid volume via osmotic retention of water. Potassium chloride (0.15%) supplies potassium ions necessary for transmembrane electrochemical gradients, maintenance of cellular membrane potential, and neuromuscular function. Combination corrects hypovolemia and hypokalemia.
| Metabolism | Not metabolized; sodium and chloride are excreted primarily unchanged by the kidneys (glomerular filtration and tubular reabsorption); potassium is actively secreted and reabsorbed in distal tubules and collecting ducts. |
| Excretion | Sodium and chloride are primarily excreted renally: >90% of filtered sodium and chloride are reabsorbed in the kidneys; excess is excreted in urine. Potassium is mainly excreted renally (approximately 90%), with minor fecal (10%) and negligible biliary elimination. |
| Half-life | Not applicable as a pharmacokinetic parameter for electrolyte solutions; the elimination half-life of infused sodium, chloride, and potassium is approximately 2-4 hours, reflecting renal clearance and distribution kinetics. In clinical context, steady-state electrolyte concentrations are achieved within 1-2 hours of continuous infusion. |
| Protein binding | Sodium, chloride, and potassium are not significantly bound to plasma proteins; protein binding is <1%. |
| Volume of Distribution | Sodium and chloride distribute primarily in extracellular fluid: Vd approximately 0.2-0.3 L/kg. Potassium distributes mainly in intracellular fluid: Vd approximately 0.6-0.7 L/kg, but initial volume of distribution for infused potassium is smaller (0.2-0.3 L/kg) before cellular uptake. |
| Bioavailability | Intravenous administration: 100% bioavailability. Not administered orally or by other routes; oral bioavailability is not clinically relevant for this formulation. |
| Onset of Action | Intravenous infusion: correction of electrolyte deficits begins within minutes; hemodynamic effects (plasma volume expansion) occur immediately with infusion. |
| Duration of Action | Intravenous infusion: effects persist as long as infusion continues; after cessation, electrolyte levels return to baseline over several hours (2-6 hours depending on renal function). Rapid distribution and excretion result in short-lived effects upon discontinuation. |
| Molecular Weight | NaCl: 58.44 Da; KCl: 74.55 Da |
Intravenous infusion: 500-1000 mL as needed to correct fluid and electrolyte deficits; rate adjusted based on patient's clinical status, typically 1-2 L/day for maintenance. Maximum rate: 20 mEq/h potassium.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment. GFR 10-50 mL/min: reduce potassium content or use with caution, monitor serum potassium; maximum potassium infusion rate 10 mEq/h. GFR <10 mL/min: avoid potassium-containing solutions unless documented hypokalemia; monitor ECG and potassium levels closely. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: monitor potassium levels; reduce rate if hyperkalemia risk. Child-Pugh C: avoid potassium-containing solutions unless essential; monitor potassium and acid-base status. |
| Pediatric use | Neonates and infants: 0.5-1 mEq/kg potassium per day; titrate based on serum levels. Children: 1-2 mEq/kg potassium per day; maximum infusion rate 0.5 mEq/kg/h. Adjust volume based on daily fluid requirements (e.g., 100 mL/kg for first 10 kg, 50 mL/kg for next 10 kg, 20 mL/kg for remaining). |
| Geriatric use | Initiate at lower infusion rates (e.g., 0.5-1 mL/min for potassium) due to decreased renal function; monitor serum electrolytes and renal function frequently; avoid volume overload (use lower volumes if heart failure or hypertension). |
| 1st trimester | Considered safe in recommended doses; essential for maintenance of fluid and electrolyte balance. No teratogenic effects reported. |
| 2nd trimester | Safe in recommended doses; monitor for electrolyte imbalances in prolonged use. |
| 3rd trimester | Safe in recommended doses; avoid excessive administration to prevent maternal or fetal hyperkalemia. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Both sodium and potassium readily cross the placenta; potassium is actively transported, sodium distributes freely. Concentrations are regulated by maternal-fetal gradients. |
| Breastfeeding | Potassium and sodium are normal constituents of human milk. This solution is compatible with breastfeeding; however, maternal electrolyte levels should be monitored to avoid excessive transfer. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Sodium chloride and potassium chloride are normal physiological constituents. No teratogenic risk is expected at therapeutic doses. Hypokalemia or hyperkalemia may affect fetal development indirectly. |
| Fetal Monitoring | Monitor serum electrolytes (Na, K, Cl), renal function, and fluid balance. Assess for signs of electrolyte imbalances such as arrhythmias, edema, or neurological changes. |
| Fertility Effects | No known effects on fertility at therapeutic doses. Severe electrolyte disturbances may impact reproductive function, but these are not drug-specific. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaAnuria or severe renal impairment with oliguriaSevere metabolic alkalosisEdematous conditions with salt retention (e.g., congestive heart failure, cirrhosis with ascites)
| Precautions | Risk of hyperkalemia or cardiac arrhythmias if potassium is administered too rapidly or in patients with impaired renal function; infusion rate should not exceed 10 mEq/h under most circumstances, Risk of hypernatremia or fluid overload in patients with cardiac failure, renal impairment, or conditions with sodium retention, Monitor serum electrolytes, fluid balance, and renal function during therapy, Use with caution in patients with oliguria, anuria, or severe renal impairment, Do not administer unless solution is clear, colorless, and container is undamaged |
| Food/Dietary | No oral food intake during IV administration. Avoid potassium-rich foods (bananas, oranges, spinach) if at risk of hyperkalemia. No known significant drug-food interactions. |
| Clinical Pearls | This balanced crystalloid solution (0.9% NaCl with 0.15% KCl) is used for maintenance fluid therapy, especially when potassium depletion is a concern. Monitor potassium levels closely in renal impairment, as this solution provides 20 mEq/L of potassium. Avoid in patients with hyperkalemia, severe renal failure, or conditions with potassium retention. Use with caution in heart failure or edema states due to sodium load. |
| Patient Advice | This fluid contains salt and potassium to maintain your body's electrolyte balance. · Your healthcare provider will monitor your kidney function and blood potassium levels during treatment. · Report any symptoms of high potassium (muscle weakness, irregular heartbeat) or fluid overload (swelling, shortness of breath). · Do not drink or consume food without consulting your doctor while receiving this intravenous fluid. |
Loading safety data…